|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
P14.87 Significance of clinical and molecular-genetic factors for prognosis in 574 adult patients with primary glioblastomaстатья Тезисы
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или ScopusДата последнего поиска статьи во внешних источниках: 3 ноября 2021 г.
- Авторы: Zolotova S., Kurmukov A., Dalechina A., Belyashova A., Golanov A.
- Журнал: Neuro-Oncology
- Том: 23
- Номер: Supplement_2
- Год издания: 2021
- Издательство: Duke University Press
- Местоположение издательства: United States
- Первая страница: ii54
- Последняя страница: ii55
- Номер статьи: P14.87
- DOI: 10.1093/neuonc/noab180.189
- Аннотация: BACKGROUNDDespite advances in the characterization of genomic alterations in glioblastoma patient survival remains poor. The aim of this single center retrospective study was to estimate prognostic factors affecting to survival for optimizing personalized treatment strategy in glioblastoma patients.MATERIAL AND METHODS574 consecutive patients with primary glioblastoma treated at the Burdenko National Medical Research Center of Neurosurgery from 2014 to 2019 were included in this study (314 male /260 female). Survival data was analyzed using Kaplan-Meier with log-rank tests to assess statistical significance. A linear regression model was built to predict overall survival.RESULTSOlder patients (> 45 years) had the worse prognosis than patients ≤ 45 (p = 2.37 * 10^-6). Female patients had advantages in overall survival (p = 0.014). Time interval from surgery to the starting of radiotherapy longer than 4 weeks was associated with worse overall survival (p = 0.062). Patients with positive IDH1/2 and MGMT had better prognosis than patients with wild type and MGMT negative (p = 0.000841, p = 0.000138, respectively). We revealed that there were significant differences in overall survival between patients who had progression on the first (p = 0.000312), second (p = 0.001046) and third (p = 0.00223) follow-up MRI after radiotherapy. Median survival times (from the date of surgery) were 17, 20, 23 months, respectively. The feature importance in the linear regression model was patient’s age, IDH1/2 mutation, MGMT promoter methylation status, progression on the first follow-up MRI and sex.CONCLUSIONOlder patient’s age, prolonged time between surgery and RT starting, male sex, negative IDH1/2 and MGMT, progression on the first MRI were associated with poor overall survival in glioblastoma patients. Our results suggested additional clinical, radiomics and molecular-genetic data should be added to improve the overall survival prediction.The results have been obtained under the support of the RFBR grant 18-29-01054 Volume 23, Issue Supplement_2, September 2021EANO 2021 ABSTRACTS
- Добавил в систему: Золотова Светлана Вячеславовна